Quest for the right Drug
קרסמבה 100 מ"ג כמוסות CRESEMBA 100 MG CAPSULES (ISAVUCONAZOLE AS SULFATE)
תרופה במרשם
תרופה בסל
נרקוטיקה
ציטוטוקסיקה
צורת מתן:
פומי : PER OS
צורת מינון:
קפסולה קשיחה : CAPSULE, HARD
עלון לרופא
מינוניםPosology התוויות
Indications תופעות לוואי
Adverse reactions התוויות נגד
Contraindications אינטראקציות
Interactions מינון יתר
Overdose הריון/הנקה
Pregnancy & Lactation אוכלוסיות מיוחדות
Special populations תכונות פרמקולוגיות
Pharmacological properties מידע רוקחי
Pharmaceutical particulars אזהרת שימוש
Special Warning עלון לרופא
Physicians Leaflet
Interactions : אינטראקציות
4.5 Interaction with other medicinal products and other forms of interaction Potential of medicinal products to affect the pharmacokinetics of isavuconazole Isavuconazole is a substrate of CYP3A4 and CYP3A5 (see section 5.2). Co-administration of medicinal products which are inhibitors of CYP3A4 and/or CYP3A5 may increase the plasma concentrations of isavuconazole. Co-administration of medicinal products which are inducers of CYP3A4 and/or CYP3A5 may decrease the plasma concentrations of isavuconazole. Medicinal products that inhibit CYP3A4/5 Co-administration of CRESEMBA with the strong CYP3A4/5 inhibitor ketoconazole is contraindicated, since this medicinal product can significantly increase plasma concentrations of isavuconazole (see sections 4.3 and 4.5). For the strong CYP3A4 inhibitor lopinavir/ritonavir, a two-fold increase in isavuconazole exposure was observed. For other strong CYP3A4 inhibitors, such as clarithromycin, indinavir and saquinavir, a less pronounced effect can be expected, based on their relative potency. No dose adjustment of CRESEMBA is necessary when co-administered with strong CYP3A4/5 inhibitors, however caution is advised as adverse drug reactions may increase (see section 4.4). No dose adjustment is warranted for moderate to mild CYP3A4/5 inhibitors. Medicinal products that induce CYP3A4/5 Co-administration of CRESEMBA with potent CYP3A4/5 inducers such as rifampicin, rifabutin, carbamazepine, long-acting barbiturates (e.g., phenobarbital), phenytoin and St. John’s wort, or with moderate CYP3A4/5 inducers such as efavirenz, nafcillin and etravirine, is contraindicated, since these medicinal products can significantly decrease plasma concentrations of isavuconazole (see section 4.3). Co-administration with mild CYP3A4/5 inducers such as aprepitant, prednisone and pioglitazone, may result in mild to moderate decreases of isavuconazole plasma levels; co-administration with mild CYP3A4/5 inducers should be avoided unless the potential benefit is considered to outweigh the risk (see section 4.4). Co-administration with high-dose ritonavir (>200 mg twice daily) is contraindicated, as at high doses ritonavir may induce CYP3A4/5 and decrease isavuconazole plasma concentrations (see section 4.3). Potential for CRESEMBA to affect exposures of other medicines Medicinal products metabolised by CYP3A4/5 Isavuconazole is a moderate inhibitor of CYP3A4/5; co-administration of CRESEMBA with medicinal products which are substrates of CYP3A4/5 may result in increased plasma concentrations of these medicinal products. Medicinal products metabolised by CYP2B6 Isavuconazole is a mild CYP2B6 inducer; co-administration of CRESEMBA may result in decreased plasma concentrations of CYP2B6 substrates. Medicinal products transported by P-gp in the intestine Isavuconazole is a mild inhibitor of P-glycoprotein (P-gp); co-administration with CRESEMBA may result in increased plasma concentrations of P-gp substrates. Medicinal products transported by BCRP Isavuconazole is an inhibitor in vitro of BCRP, and plasma concentrations of substrates of BCRP may therefore be increased. Caution is advised when CRESEMBA is given concomitantly with substrates of BCRP. Medicinal products renally excreted via transport proteins Isavuconazole is a mild inhibitor of the organic cation transporter 2 (OCT2). Co-administration of CRESEMBA with medicinal products which are substrates of OCT2 may result in increased plasma concentrations of these medicinal products. Uridine diphosphate-glucuronosyltransferases (UGT) substrates Isavuconazole is a mild inhibitor of UGT. Co-administration of CRESEMBA with medicinal products which are substrates of UGT may result in mildly increased plasma concentrations of these medicinal products. Interaction table Interactions between isavuconazole and co-administered medicinal products are listed in Table 1 (increase is indicated as “↑”, decrease as “↓”), ordered by therapeutic class. Unless otherwise stated, studies detailed in Table 1 have been performed with the recommended dose of CRESEMBA. Table 1 Interactions Co-administered medicinal Effects on drug concentrations / Recommendation concerning product by therapeutic area Geometric Mean Change (%) co-administration in AUC, Cmax (Mode of action) Anticonvulsants Carbamazepine, phenobarbital Isavuconazole concentrations may The concomitant administration of and phenytoin decrease (CYP3A induction by CRESEMBA and carbamazepine, (strong CYP3A4/5 inducers) carbamazepine, phenytoin and phenytoin and long-acting long-acting barbiturates such as barbiturates such as phenobarbital is phenobarbital). contraindicated. Antibacterials Rifampicin Isavuconazole: The concomitant administration (strong CYP3A4/5 inducer) AUCtau: ↓ 90% of CRESEMBA and rifampicin Cmax: ↓ 75% is contraindicated. (CYP3A4/5 induction) Rifabutin Not studied. The concomitant administration (strong CYP3A4/5 inducer) Isavuconazole concentrations may of CRESEMBA and rifabutin is significantly decrease. contraindicated. (CYP3A4/5 induction) Nafcillin Not studied. The concomitant administration (moderate CY3A4/5 inducer) Isavuconazole concentrations may of CRESEMBA and nafcillin is significantly decrease. contraindicated. (CYP3A4/5 induction) Clarithromycin Not studied. No CRESEMBA dose (strong CYP3A4/5 inhibitor) Isavuconazole concentrations may adjustment necessary; caution is increase. advised as adverse drug reactions may increase. (CYP3A4/5 inhibition) Antifungals Ketoconazole Isavuconazole: The concomitant administration (strong CYP3A4/5 inhibitor) AUCtau: ↑ 422% of CRESEMBA and Cmax: ↑ 9% ketoconazole is contraindicated. (CYP3A4/5 inhibition) Herbal medicines St John’s wort Not studied. The concomitant administration (strong CYP3A4/5 inducer) Isavuconazole concentrations may of CRESEMBA and St John’s significantly decrease. wort is contraindicated. (CYP3A4 induction). Immunosuppresants Ciclosporin, sirolimus, Ciclosporin: No CRESEMBA dose tacrolimus AUCinf: ↑ 29% adjustment necessary. (CYP3A4/5 substrates) Cmax: ↑ 6% Ciclosporin, sirolimus, tacrolimus: monitoring of plasma Sirolimus: levels and appropriate dose AUCinf: ↑ 84% adjustment if required. Cmax: ↑ 65% Tacrolimus: AUCinf: ↑ 125% Cmax: ↑ 42% (CYP3A4 inhibition) Mycophenolate mofetil (MMF) Mycophenolic acid (MPA, active No CRESEMBA dose (UGT substrate) metabolite) : adjustment necessary. AUCinf: ↑ 35% MMF: monitoring for MPA- Cmax: ↓ 11% related toxicities is advised. (UGT inhibition) Prednisone Prednisolone (active metabolite): Co-administration should be (CYP3A4 substrate) AUCinf: ↑ 8% avoided unless the potential Cmax: ↓ 4% benefit is considered to outweigh the risk. (CYP3A4 inhibition) Isavuconazole concentrations may decrease. (CYP3A4/5 induction) Opioids Short-acting opiates Not studied. No CRESEMBA dose (alfentanyl, fentanyl) Short-acting opiate concentrations adjustment necessary. (CYP3A4/5 substrate) may increase. Short-acting opiates (alfentanyl, fentanyl): careful monitoring for (CYP3A4/5 inhibition). any occurrence of drug toxicity, and dose reduction if required. Methadone S-methadone (inactive opiate No CRESEMBA dose (CYP3A4/5, 2B6 and 2C9 isomer) adjustment necessary. substrate) AUCinf: ↓ 35% Methadone: no dose adjustment Cmax: ↑ 1% required. 40% reduction in terminal half-life R-methadone (active opiate isomer). AUCinf: ↓ 10% Cmax: ↑ 4% (CYP2B6 induction) Anti-cancer Vinca alkaloids (vincristine, Not studied. No CRESEMBA dose vinblastine) Vinca alkaloid concentrations may adjustment necessary. (P-gp substrates) increase. Vinca alkaloids: careful monitoring for any occurrence of (P-gp inhibition) drug toxicity, and dose reduction if required. Cyclophosphamide Not studied. No CRESEMBA dose (CYP2B6, CYP3A4 substrate) Active metabolites of adjustment necessary. cyclophosphamide may increase or Cyclophosphamide: careful decrease. monitoring for any occurrence of lack of efficacy or increased (CYP2B6 induction, CYP3A4 toxicity, and dose adjustment if inhibition)) required.. Methotrexate Methotrexate: No CRESEMBA dose (BCRP, OAT1, OAT3 AUCinf: ↓ 3% adjustment necessary. substrate) Cmax: ↓ 11% Methotrexate: no dose adjustment required. 7-hydroxymetabolite: AUCinf: ↑ 29% Cmax: ↑ 15% (Mechanism unknown) Other anticancer agents Not studied. No CRESEMBA dose (daunorubicin, doxorubicin, Daunorubicin, doxorubicin, adjustment necessary. imatinib, irinotecan, lapatinib, imatinib, irinotecan, lapatinib, Daunorubicin, doxorubicin, mitoxantrone, topotecan) mitoxantrone, topotecan imatinib, irinotecan, lapatinib, (BCRP substrates) concentrations may increase. mitoxantrone or topotecan: careful monitoring for any (BCRP inhibition) occurrence of drug toxicity, and dose reduction if required. Antiemetics Aprepitant Not studied. Co-administration should be (mild CYP3A4/5 inducer) Isavuconazole concentrations may avoided unless the potential decrease. benefit is considered to outweigh the risk. (CYP3A4/5 induction) Antidiabetics Metformin Metformin: No CRESEMBA dose (OCT1, OCT2 and MATE1 AUCinf: ↑ 52% adjustment necessary. substrate) Cmax: ↑ 23% Metformin: dose reduction may be required. (OCT2 inhibition) Repaglinide Repaglinide: No CRESEMBA dose (CYP2C8 and OATP1B1 AUCinf: ↓ 8% adjustment necessary. substrate) Cmax: ↓ 14% Repaglinide: no dose adjustment required. Pioglitazone Not studied. Co-administration should be (mild CYP3A4/5 inducer) Isavuconazole concentrations may avoided unless the potential decrease. benefit is considered to outweigh the risk. (CYP3A4/5 induction) Anticoagulants Dabigatran etexilate Not studied. No CRESEMBA dose (P-gp substrate) Dabigatran etexilate concentrations adjustment necessary. may increase. Dabigatran etexilate has a narrow therapeutic index and should be (P-gp inhibition). monitored, and dose reduction if required. Warfarin S-warfarin No CRESEMBA dose (CYP2C9 substrate) AUCinf: ↑ 11% adjustment necessary. Cmax: ↓ 12% Warfarin: no dose adjustment R-warfarin required. AUCinf: ↑ 20% Cmax: ↓ 7% Antiretroviral agents Lopinavir 400 mg / Ritonavir Lopinavir: No CRESEMBA dose 100 mg AUCtau: ↓ 27% adjustment necessary; caution is (CYP3A4/5 strong inhibitors Cmax: ↓ 23% advised as adverse drug reactions and substrates) Cmin, ss: ↓ 16%a) may increase. Ritonavir: AUCtau: ↓ 31% Lopinavir/ritonavir: no dose Cmax: ↓ 33% adjustment for lopinavir 400 mg / ritonavir 100 mg every 12 hours (Mechanism unknown) required, but careful monitoring for any occurrence of lack of Isavuconazole: anti-viral efficacy. AUCtau: ↑ 96% Cmax: ↑ 74% (CYP3A4/5 inhibition) Ritonavir (at doses >200 mg Not studied. The concomitant administration every 12 hours) Ritonavir at high doses may of CRESEMBA and high doses (strong CYP3A4/5 inducer) significantly decrease of ritonavir (>200 mg every 12 isavuconazole concentrations. hours) is contraindicated. (CYP3A4/5 induction) Efavirenz Not studied. The concomitant administration (CYP3A4/5 moderate inducer Efavirenz concentrations may of CRESEMBA and efavirenz is and CYP2B6 substrate) decrease. contraindicated. . (CYP2B6 induction) Isavuconazole drug concentrations may significantly decrease. (CYP3A4/5 induction) Etravirine Not studied. The concomitant administration (moderate CYP3A4/5 inducer) Isavuconazole concentrations may of CRESEMBA and etravirine is significantly decrease. contraindicated. (CYP3A4/5 induction) Indinavir Indinavir:b) No CRESEMBA dose (CYP3A4/5 strong inhibitor AUCinf: ↓ 36% adjustment necessary; caution is and substrate) Cmax: ↓ 52% advised as adverse drug reactions may increase. (Mechanism unknown) Indinavir: careful monitoring for any occurrence of lack of anti- Isavuconazole concentrations may viral efficacy, and dose increase increase. if required. (CYP3A4/5 inhibition) Saquinavir Not studied. No CRESEMBA dose (strong CYP3A4 inhibitor) Saquinavir concentrations may adjustment necessary; caution is decrease (as observed with advised as adverse drug reactions lopinavir/ritonavir) or increase may increase. (CYP3A4 inhibition). Saquinavir: careful monitoring for any occurrence of drug Isavuconazole concentrations may toxicity and /or lack of anti-viral increase. efficacy, and dose adjustment if required (CYP3A4/5 inhibition). Other protease inhibitors (e.g. Not studied. No isavuconazole dose fosamprenavir) Protease inhibitor concentrations adjustment necessary. (CYP3A4/5 strong or moderate may decrease (as observed with Protease inhibitors: careful inhibitors and substrates) lopinavir/ritonavir) or increase. monitoring for any occurrence of drug toxicity and /or lack of (CYP3A4 inhibition) anti-viral efficacy, and dose adjustment if required. Isavuconazole concentrations may increase. (CYP3A4/5 inhibition) Other NNRTI (e.g., Not studied. No CRESEMBA dose delavirdine, and nevirapine) NNRTI concentrations may adjustment necessary. (CYP3A4/5 and 2B6 inducers decrease (CYP2B6 induction by NNRTIs: careful monitoring for and substrates) isavuconazole) or increase. any occurrence of drug toxicity and/or lack of anti-viral efficacy, (CYP3A4/5 inhibition) and dose adjustment if required. Antiacids Esomeprazole Isavuconazole: No CRESEMBA dose (CYP2C19 substrate and AUCtau: ↑ 8% adjustment necessary. gastric pH ↑) Cmax: ↑ 5% Esomeprazole: no dose adjustment required. Omeprazole Omeprazole: No CRESEMBA dose (CYP2C19 substrate and AUCinf: ↓ 11% adjustment necessary. gastric pH ↑) Cmax: ↓ 23% Omeprazole: no dose adjustment required. Lipid-lowering agents Atorvastatin and other statins Atorvastatin : No CRESEMBA dose (CYP3A4 substrates e.g., AUCinf: ↑ 37% adjustment necessary. simvastatin, lovastatin, Cmax: ↑ 3% Based on results with rosuvastatin) Other statins were not studied. atorvastatin, no statin dose (CYP3A4/5 and/or BCRP Statins concentrations may adjustment required. Monitoring substrates)) increase. of adverse reactions typical of statins is advised. (CYP3A4/5 or BCRP inhibition) Antiarrhythmics Digoxin Digoxin: No CRESEMBA dose (P-gp substrate) AUCinf: ↑ 25% adjustment necessary. Cmax: ↑ 33% Digoxin: serum digoxin concentrations should be (P-gp inhibition) monitored and used for titration of the digoxin dose. Oral contraceptives Ethinyl oestradiol and Ethinyl oestradiol No CRESEMBA dose norethindrone AUCinf: ↑ 8% adjustment necessary. (CYP3A4/5 substrates) Cmax: ↑ 14% Ethinyl oestradiol and Norethindrone norethindrone: no dose AUCinf: ↑ 16% adjustment required. Cmax: ↑ 6% Antitussives Dextromethorphan Dextromethorphan: No CRESEMBA dose (CYP2D6 substrate) AUCinf: ↑ 18% adjustment necessary. Cmax: ↑ 17% Dextromethorphan: no dose Dextrorphan (active metabolite): adjustment required. AUCinf: ↑ 4% Cmax: ↓ 2% Benzodiazepines Midazolam Oral midazolam: No CRESEMBA dose (CYP3A4/5 substrate) AUCinf: ↑ 103% adjustment necessary. Cmax: ↑ 72% Midazolam: careful monitoring of clinical signs and symptoms (CYP3A4 inhibition) recommended, and dose reduction if required. Antigout agent Colchicine Not studied. No CRESEMBA dose (P-gp substrate) Colchicine concentrations may adjustment necessary. increase. Colchicine has a narrow therapeutic index and should be (P-gp inhibition) monitored, dose reduction if required. Natural products Caffeine Caffeine: No CRESEMBA dose (CYP1A2 substrate) AUCinf: ↑ 4% adjustment necessary. Cmax: ↓ 1% Caffeine: no dose adjustment required. Smoking cessation aids Bupropion Bupropion: No CRESEMBA dose (CYP2B6 substrate) AUCinf: ↓ 42% adjustment necessary. Cmax: ↓ 31% Bupropion: dose increase if required. (CYP2B6 induction) NNRTI, non-nucleoside reverse-transcriptase inhibitor; P-gp, P-glycoprotein. a) % decrease of the mean trough level values b) Indinavir was only studied after a single dose of 400 mg isavuconazole. AUCinf = area under the plasma concentration-time profiles extrapolated to infinity; AUCtau = area under the plasma concentration-time profiles during the 24 h interval at steady state; Cmax = peak plasma concentration; Cmin,ss = trough levels at steady state.
פרטי מסגרת הכללה בסל
א. התרופה תינתן לטיפול במקרים האלה:1. זיהום פטרייתי מסוג Mucor (Zygomycosis) בחולים רפרקטורים או שאינם יכולים לקבל טיפול ב-Amphotericin B או Amphotericin B, lyposomal. 2. זיהום פטרייתי מסוג Aspergillosis חודרני, בחולים מבוגרים שלא יכולים לקבל טיפול עם Voriconazole, העונים על אחד מאלה:א. חולים עם כשל כלייתי הזקוקים לטיפול במתן תוך ורידי;ב. חולים עם חשד קליני לזיהום בעובש פולשני ללא זיהוי מיקרוביולוגי, שאינם מגיבים לטיפול ב- Voriconazole;ג. חולים הזקוקים לטיפול בתרופות אונקולוגיות שעוברות מטבוליזם במסלול ציטוכרום P450;ד. חולים שפיתחו הפרעה כבדית, עורית או עינית משמעותית תחת טיפול ב- Voriconazole.הטיפול לא יינתן בשילוב עם Posaconazole. ב. הטיפול בתרופה יעשה לפי מרשם של רופא מומחה במחלות זיהומיות
מסגרת הכללה בסל
התוויות הכלולות במסגרת הסל
התוויה | תאריך הכללה | תחום קליני | Class Effect | מצב מחלה |
---|---|---|---|---|
זיהום פטרייתי מסוג Aspergillosis חודרני, בחולים מבוגרים שלא יכולים לקבל טיפול עם Voriconazole, העונים על אחד מאלה: א. חולים עם כשל כלייתי הזקוקים לטיפול במתן תוך ורידי; ב. חולים עם חשד קליני לזיהום בעובש פולשני ללא זיהוי מיקרוביולוגי, שאינם מגיבים לטיפול ב- Voriconazole; ג. חולים הזקוקים לטיפול בתרופות אונקולוגיות שעוברות מטבוליזם במסלול ציטוכרום P450; ד. חולים שפיתחו הפרעה כבדית, עורית או עינית משמעותית תחת טיפול ב- Voriconazole. הטיפול לא יינתן בשילוב עם Posaconazole. | 30/01/2020 | מחלות זיהומיות | Aspergillosis, invasive | |
זיהום פטרייתי מסוג Mucor (Zygomycosis) בחולים רפרקטורים או שאינם יכולים לקבל טיפול ב-Amphotericin B או Amphotericin B, lyposomal. | 16/01/2019 | מחלות זיהומיות | Mucor, Zygomycosis |
שימוש לפי פנקס קופ''ח כללית 1994
לא צוין
תאריך הכללה מקורי בסל
16/01/2019
הגבלות
תרופה מוגבלת לרישום ע'י רופא מומחה או הגבלה אחרת
מידע נוסף
עלון מידע לצרכן
09.06.21 - עלון לצרכן אנגלית 09.06.21 - עלון לצרכן עברית 09.06.21 - עלון לצרכן ערבית 12.10.22 - עלון לצרכן אנגלית 12.10.22 - עלון לצרכן עברית 12.10.22 - עלון לצרכן ערבית 07.06.23 - עלון לצרכן אנגלית 07.05.23 - עלון לצרכן עברית 07.06.23 - עלון לצרכן ערבית 05.11.24 - עלון לצרכן אנגלית 05.11.24 - עלון לצרכן עברית 08.12.20 - החמרה לעלון 31.03.21 - החמרה לעלון 08.06.21 - החמרה לעלון 19.07.21 - החמרה לעלון 11.04.22 - החמרה לעלון 02.10.22 - החמרה לעלון 07.05.23 - החמרה לעלון 12.08.24 - החמרה לעלון 05.11.24 - החמרה לעלוןלתרופה במאגר משרד הבריאות
קרסמבה 100 מ"ג כמוסות